Breast Cancer: Diagnosis and Staging — MCQs
Fluorescence in situ hybridization (FISH) is required in which of the following interpretations of Her2/neu?
Which of the following is not true about breast cancer?
N3a TNM staging of head and neck tumors (AJCC 8th edition) shows:
What is not an advantage of USG over mammography?
The presence of estrogen receptors is associated with certain types of breast cancer. Which of the following factors is known to increase the risk of developing breast cancer?
In which of the following types of breast carcinoma would you consider a biopsy of the opposite breast?
Gold standard investigation for breast carcinoma screening in a patient with silicone breast implants
Mammography can be best used in?
Which of the following stages of lip carcinoma does not have nodal involvement?
A 45-year-old lady presents with history of a painless lump in the right breast since 1 month. On examination, the lump is hard, 3 x 4 cm in size in the upper outer quadrant and is not fixed to the skin or the underlying structures. The axilla reveals firm mobile lymph nodes (level I). Rest of systemic examination is normal. The clinical stage of this disease is :
Breast Cancer: Diagnosis and Staging Indian Medical PG Practice Questions and MCQs
Question 1: Fluorescence in situ hybridization (FISH) is required in which of the following interpretations of Her2/neu?
- A. All of the options
- B. 2+ (Correct Answer)
- C. 1+
- D. 3+
Explanation: ***Correct: 2+*** A **Her2/neu immunohistochemistry (IHC) score of 2+** is considered **equivocal**, meaning it's uncertain whether Her2/neu is overexpressed. In such cases, **Fluorescence In Situ Hybridization (FISH)** is required to determine the amplification status of the *HER2* gene, which guides treatment decisions regarding anti-HER2 therapy (trastuzumab) [1], [2]. The 2+ score shows incomplete and weak to moderate membrane staining in >10% of tumor cells, necessitating gene amplification confirmation. *Incorrect: All of the options* While FISH is crucial for equivocal interpretations, it is **not required for all** possible Her2/neu IHC results [2]. Some scores (1+ and 3+) definitively indicate Her2/neu status without requiring confirmatory testing. Routinely performing FISH for all IHC scores would be unnecessary and costly. *Incorrect: 1+* An IHC score of **1+** indicates **no Her2/neu overexpression** (faint/barely perceptible incomplete membrane staining in >10% of tumor cells). In this situation, the patient is considered **Her2-negative**, and FISH testing is **not required** as the result is clearly negative. *Incorrect: 3+* An IHC score of **3+** indicates **clear Her2/neu overexpression** (strong, complete membrane staining in >10% of tumor cells) [1]. Patients with an IHC 3+ score are considered **Her2-positive**, and typically **FISH testing is not required** to confirm this result, as the overexpression is unequivocal [2]. **References:** [1] Cross SS. Underwood's Pathology: A Clinical Approach. 6th ed. (Basic Pathology) introduces the student to key general principles of pathology, both as a medical science and as a clinical activity with a vital role in patient care. Part 2 (Disease Mechanisms) provides fundamental knowledge about the cellular and molecular processes involved in diseases, providing the rationale for their treatment. Part 3 (Systematic Pathology) deals in detail with specific diseases, with emphasis on the clinically important aspects., pp. 256-259. [2] Kumar V, Abbas AK, et al.. Robbins and Cotran Pathologic Basis of Disease. 9th ed. The Breast, pp. 1064-1066.
Question 2: Which of the following is not true about breast cancer?
- A. Family history is a risk factor
- B. Paget’s disease affects the nipple
- C. Lobular carcinoma is most common (Correct Answer)
- D. Estrogen exposure increases risk
Explanation: ***Lobular carcinoma is most common*** - This statement is **incorrect** because **invasive ductal carcinoma (IDC)** accounts for the majority (**70-80%**) of all breast cancers. - While **invasive lobular carcinoma (ILC)** is the second most common type, it only represents about **5-15%** of cases. *Family history is a risk factor* - A **positive family history**, especially in a first-degree relative, significantly increases the risk of breast cancer due to inherited genetic mutations like **BRCA1** and **BRCA2**. - These mutations impair DNA repair, leading to uncontrolled cell growth. *Paget’s disease affects the nipple* - **Paget's disease of the nipple** is a rare form of breast cancer that presents as an eczematous lesion of the nipple and areola. - It is often associated with an **underlying invasive or in-situ ductal carcinoma**. *Estrogen exposure increases risk* - Prolonged or higher levels of **estrogen exposure** are known risk factors for breast cancer, as estrogen stimulates the growth of hormone-receptor-positive breast cancer cells. - Factors increasing estrogen exposure include **early menarche, late menopause, obesity**, and **hormone replacement therapy**.
Question 3: N3a TNM staging of head and neck tumors (AJCC 8th edition) shows:
- A. Metastasis in a lymph node >6 cm (Correct Answer)
- B. Metastasis in lymph nodes >2 cm
- C. Metastasis in lymph nodes >5 cm
- D. None of the options
Explanation: ***Metastasis in a lymph node >6 cm*** - **N3a disease** in head and neck cancer staging (AJCC 8th edition) specifically refers to metastasis in a single lymph node larger than 6 cm in greatest dimension **without extranodal extension (ENE)**. - This applies to oral cavity, oropharynx (HPV-negative), hypopharynx, and larynx cancers. - **Note:** N3 staging also includes **N3b** (metastasis in any node with clinically overt ENE), but this question specifically asks about N3a criteria. *Metastasis in lymph nodes >2 cm* - Lymph nodes in the 2-3 cm range typically fall within **N1 or N2a categories**, depending on laterality and number of involved nodes. - **N3a disease** requires a single lymph node to exceed 6 cm in greatest dimension without ENE. *Metastasis in lymph nodes >5 cm* - A lymph node between 3-6 cm is usually classified as **N2 disease** (N2a if single ipsilateral ≤6 cm, N2b if multiple ipsilateral ≤6 cm, N2c if bilateral or contralateral ≤6 cm). - To be classified as **N3a**, the lymph node must be **>6 cm** without extranodal extension. *None of the options* - This option is incorrect because the first option accurately describes the size criterion for **N3a TNM staging** in head and neck tumors according to AJCC 8th edition guidelines. - While N3 staging has two subcategories (N3a and N3b), the size criterion of >6 cm correctly defines N3a disease.
Question 4: What is not an advantage of USG over mammography?
- A. Can be used for guided biopsy
- B. Superior detection of microcalcifications (Correct Answer)
- C. In young females with dense breasts
- D. Can be used to differentiate solid VS cystic
Explanation: ***Superior detection of microcalcifications*** - **Mammography** is the gold standard for detecting **microcalcifications**, which can be a key indicator of **ductal carcinoma in situ (DCIS)** or early invasive breast cancer. - **Ultrasound (USG)** has limited sensitivity for detecting and characterizing microcalcifications. *Can be used for guided biopsy* - **USG-guided biopsy** is a common and advantageous technique for obtaining tissue samples from suspicious lesions in the breast or other organs. - This allows for **real-time visualization** of the needle, improving accuracy and reducing complications. *Can be used to differentiate solid VS cystic* - **USG** excels at distinguishing between **solid masses and fluid-filled cysts** due to differences in sound wave reflection. - This capability is crucial in characterizing breast lesions and often eliminates the need for further invasive procedures for benign cysts. *In young females with dense breasts* - **Dense breast tissue** in young females can obscure lesions on mammography, making interpretation difficult. - **USG** is particularly valuable in this population because it is not hindered by breast density and can provide a clearer view of underlying pathology.
Question 5: The presence of estrogen receptors is associated with certain types of breast cancer. Which of the following factors is known to increase the risk of developing breast cancer?
- A. Smoking
- B. Nulliparity (Correct Answer)
- C. Oral contraceptives
- D. Multiparity
Explanation: Nulliparity - **Nulliparity** (never having given birth) increases the risk of breast cancer because a woman has more **menstrual cycles** throughout her reproductive life, leading to greater lifetime exposure to **estrogen** [1]. - Childbirth and breastfeeding are thought to provide a degree of protection against breast cancer, possibly due to hormonal changes, cellular differentiation, and a reduction in the total number of menstrual cycles. *Smoking* - While smoking is a known risk factor for many cancers, its association with breast cancer is **controversial** and less direct compared to other factors. - The evidence linking smoking directly to increased breast cancer risk is **inconsistent** across studies, with some finding a modest link, especially in women who start smoking at an early age. *Oral contraceptives* - The use of **oral contraceptives** has been shown to have a **minimal** and transient effect on breast cancer risk. - This risk is often considered small and resolves over time after discontinuation, and the overall benefit-risk profile is still favorable for many women. *Multiparity* - **Multiparity** (having multiple live births) is generally associated with a **decreased risk** of breast cancer, particularly if the first full-term pregnancy occurs at a younger age. - The hormonal changes during pregnancy and the differentiation of breast tissue are believed to provide protective effects against malignant transformation.
Question 6: In which of the following types of breast carcinoma would you consider a biopsy of the opposite breast?
- A. Lobular carcinoma (Correct Answer)
- B. Comedo carcinoma
- C. Medullary carcinoma
- D. Adenocarcinoma-poorly differentiated
Explanation: ***Lobular carcinoma*** - **Invasive lobular carcinoma (ILC)** is known for its **multicentricity** (multiple foci within the same breast) and a higher incidence of **bilateral involvement** compared to other breast cancer types. - Due to its infiltrating growth pattern without significant desmoplasia, ILC can be **clinically subtle** and difficult to detect by imaging, thus biopsy of the contralateral breast may be considered if there are any suspicious findings. *Comedo carcinoma* - This is a subtype of **ductal carcinoma in situ (DCIS)** characterized by central necrosis, calcifications, and high-grade nuclei confined to the ducts. - While DCIS can recur or progress, its primary concern is typically within the affected breast, and it does not inherently carry a significantly increased risk of contralateral involvement requiring routine biopsy. *Medullary carcinoma* - **Medullary carcinoma** is a rare subtype of invasive ductal carcinoma known for its distinct histological features, including a pushing border, prominent lymphocytic infiltrate, and high-grade nuclei. - It generally has a **better prognosis** than other invasive ductal carcinomas and does not have a characteristically high incidence of bilateral involvement that would routinely warrant a contralateral breast biopsy. *Adenocarcinoma-poorly differentiated* - This term describes an **invasive ductal carcinoma** with a high histologic grade, indicating aggressive features and poor differentiation. - While any invasive breast cancer carries some risk of bilateral disease, poorly differentiated adenocarcinoma does not have the uniquely high predisposition for **contralateral synchronous or metachronous disease** that is characteristic of lobular carcinoma.
Question 7: Gold standard investigation for breast carcinoma screening in a patient with silicone breast implants
- A. Mammography
- B. CT scan
- C. USG
- D. MRI (Correct Answer)
Explanation: ***MRI*** - **MRI** is considered the **gold standard** for breast cancer screening in patients with silicone breast implants due to its superior ability to visualize breast tissue through the implant and detect subtle lesions. - It offers **high sensitivity** in detecting both implant rupture and early malignancies, often providing better clarity than mammography in augmented breasts where implants can obscure tissue. *Mammography* - While a standard screening tool, **mammography** can be limited in patients with silicone implants because the implants can **obscure adjacent breast tissue**, making detection of small masses challenging. - Special views (e.g., **Eklund views**) can be used, but sensitivity is still reduced compared to MRI in augmented breasts. *CT scan* - **CT scans** are not routinely used for primary breast cancer screening due to their use of **ionizing radiation** and lower sensitivity for detecting early breast lesions compared to MRI. - CT is more commonly used for **staging** advanced cancers or evaluating complex masses detected by other modalities. *USG* - **Ultrasound (USG)** is a valuable complementary tool, especially for evaluating palpable lumps or clarifying findings from mammography, but it is **operator-dependent** and has a lower overall sensitivity for general screening compared to MRI. - It is particularly useful for differentiating between **cystic and solid masses** and detecting implant ruptures but is not the gold standard for comprehensive screening in augmented breasts.
Question 8: Mammography can be best used in?
- A. Early breast carcinoma (Correct Answer)
- B. Mastitis
- C. Fibroadenoma
- D. Phylloides tumor
Explanation: ***Early breast carcinoma*** - **Mammography** is the gold standard for **early detection of breast carcinoma**, particularly for identifying **microcalcifications** and small masses before they are palpable. - It plays a crucial role in **screening asymptomatic women** to reduce breast cancer mortality. *Mastitis* - **Mastitis** is an **inflammatory condition** of the breast, often associated with infection, which is usually diagnosed clinically. - While mammography might show diffuse **increased density**, it is not the primary diagnostic tool and often has limited value due to inflammatory changes masking pathology. *Fibroadenoma* - **Fibroadenomas** are **benign breast tumors** common in younger women, typically appearing as well-circumscribed masses on mammography. - While mammography can detect them, their characterization often requires **ultrasound** and **biopsy** for definitive diagnosis, as differentiation from malignant lesions can be challenging. *Phylloides tumor* - A **Phylloides tumor** is a rare tumor that can be benign, borderline, or malignant, and it typically presents as a rapidly growing, palpable mass. - Mammography may show a well-defined mass, but **ultrasound** and **core needle biopsy** are essential for accurate diagnosis and distinction from fibroadenomas or malignancy.
Question 9: Which of the following stages of lip carcinoma does not have nodal involvement?
- A. T2N1
- B. T3N0 (Correct Answer)
- C. T2N2
- D. T1N1
Explanation: ***T3N0*** - The **'N' classification** in the TNM staging system refers to **nodal involvement**. A stage with **'N0' indicates no regional lymph node metastasis**. - A **T3 lesion** signifies a large primary tumor, but if it's accompanied by **N0**, it means there's no evidence of spread to the lymph nodes. *T2N1* - The **'N1' classification** indicates the presence of **regional lymph node metastasis**, specifically in a **single ipsilateral lymph node** that is 3 cm or less in its greatest dimension. - This stage therefore **does have nodal involvement**, contradicting the premise of the question. *T2N2* - The **'N2' classification** signifies more advanced regional lymph node metastasis, such as a **single ipsilateral lymph node** greater than 3 cm but not more than 6 cm. - It could also refer to **multiple ipsilateral lymph nodes**, none greater than 6 cm, or bilateral/contralateral lymph nodes, none greater than 6 cm. In all these cases, **nodal involvement is present**. *T1N1* - Similar to T2N1, the **'N1' component** in T1N1 indicates the presence of **regional lymph node metastasis** in a single ipsilateral lymph node of 3 cm or less. - Therefore, this stage **does involve nodal spread**, despite having a smaller primary tumor (T1).
Question 10: A 45-year-old lady presents with history of a painless lump in the right breast since 1 month. On examination, the lump is hard, 3 x 4 cm in size in the upper outer quadrant and is not fixed to the skin or the underlying structures. The axilla reveals firm mobile lymph nodes (level I). Rest of systemic examination is normal. The clinical stage of this disease is :
- A. cT₃ N₁ Mₓ
- B. cT₂ N₁ Mₓ (Correct Answer)
- C. cT₁ N₁ Mₓ
- D. cT₃ N₂ Mₓ
Explanation: **cT₂ N₁ Mₓ** - The tumor size of **3 x 4 cm** falls within the T2 classification (>2 cm but ≤5 cm). The description of the lump being "not fixed to the skin or the underlying structures" further supports a T2 (or lower) classification, as fixation would suggest a more advanced T stage (T4). - The presence of "firm mobile lymph nodes (level I)" indicates involvement of regional lymph nodes, which is classified as **N1** in breast cancer staging. An "Mx" designation means that distant metastasis cannot be assessed clinically without further investigation. *cT₃ N₁ Mₓ* - A **T3 classification** would apply if the tumor measured **greater than 5 cm** in its largest dimension, which is not the case here, as the lump is 3 x 4 cm. - While the **N1 and Mx** components are consistent with the findings, the T component is incorrect for the given tumor size. *cT₁ N₁ Mₓ* - A **T1 classification** is used for tumors that are **2 cm or less in greatest dimension**. The given tumor size of 3 x 4 cm clearly exceeds this limit. - The **N1 and Mx** components are consistent, but the T component is inappropriate for the described tumor size. *cT₃ N₂ Mₓ* - This option is incorrect on two counts: the **T3 classification** is wrong for a 3 x 4 cm tumor (should be >5 cm), and the **N2 classification** is also incorrect. - **N2** would indicate metastases to **ipsilateral axillary lymph nodes that are fixed or matted**, or in ipsilateral internal mammary lymph nodes in the absence of clinically apparent axillary lymph node metastases. The description states "firm mobile lymph nodes (level I)," which corresponds to N1, not N2.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free